Not recruiting yet
Predictors of BCR After RARP for Localized Prostate Cancer: A Retrospective Analysis
NCT07682584 · First Affiliated Hospital of Fujian Medical University · Updated 6 July 2026
- What is being tested
- Not stated
- For
- Prostate Cancer; Biochemical Recurrence
- Kind of study
- Watches patients without assigning a treatment. No drug phase (a device or procedure study).
- Who can join
- Ages Not stated. About 200 people. The full rules are on the registry page.
- Where
- Not stated
- When
- Starts or started 15 July 2026, ends 30 Sept 2026. Registered 6 July 2026.
- Results
- None posted yet.
In the researchers' words
This retrospective study aims to identify predictive factors for biochemical recurrence (BCR) in patients with localized prostate cancer who underwent robot-assisted radical prostatectomy (RARP). BCR is defined as a rise in prostate-specific antigen (PSA) levels after surgery, which may indicate residual or recurrent disease. We will analyze clinical, imaging, and pathological data from patients treated at Fujian Medical University Affiliated First Hospital between January 2024 and May 2026. Key variables include preoperative PSA, Gleason score, pathological T stage, surgical margin status, perineural invasion, prostate volume, MRI-based parameters (e.g., Pi-RADS score, SUVmax on PSMA PET/CT), and inflammatory markers. Using logistic regression and machine learning approaches (random forest, XGBoost, SVM), we will develop and internally validate a predictive model to estimate individual BCR risk. The goal is to improve post-surgical risk stratification, guide personalized monitoring, and support clinical decision-making regarding adjuvant therapy. This research has received ethical approval. Data will be anonymized and handled confidentially. Findings will be disseminated to inform clinical practice and future research.